Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery


Baselga J 's Articles

[31013327] Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Loi Sherene , Michiels Stefan , Baselga Jose , Bartlett John M S , Singhal Sandeep K , Sabine Vicky S , Sims Andrew H , Sahmoud Tarek , Michael Dixon J , Piccart Martine J , Sotiriou Christos ,

[30976844] Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Kirschbrown Whitney P , Kågedal Matts , Wang Bei , Lindbom Lars , Knott Adam , Mack Rachelle , Monemi Sharareh , Nijem Ihsan , Girish Sandhya , Freeman Christie , Fumagalli Debora , McConnell Robin , Jerusalem Guy , Twelves Chris , Baselga José , von Minckwitz Gunter , Bines José , Garg Amit ,

[30943409] PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.

Toska Eneda , Castel Pau , Chhangawala Sagar , Arruabarrena-Aristorena Amaia , Chan Carmen , Hristidis Vasilis C , Cocco Emiliano , Sallaku Mirna , Xu Guotai , Park Jane , Minuesa Gerard , Shifman Sophie G , Socci Nicholas D , Koche Richard , Leslie Christina S , Scaltriti Maurizio , Baselga José ,

[30862692] Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail ,

[30845698] High Ampacity Carbon Nanotube Materials.

Mokry Guillermo , Pozuelo Javier , Vilatela Juan J , Sanz Javier , Baselga Juan ,

[30814109] Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Di Cosimo Serena , Appierto Valentina , Pizzamiglio Sara , Tiberio Paola , Iorio Marilena V , Hilbers Florentine , de Azambuja Evandro , de la Peña Lorena , Izquierdo Miguel , Huober Jens , Baselga José , Piccart Martine , de Braud Filippo G , Apolone Giovanni , Verderio Paolo , Daidone Maria Grazia ,

[30770494] Correction: F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Yingbing , Ayres Karen L , Goldman Debra A , Dickler Maura N , Bardia Aditya , Mayer Ingrid A , Winer Eric , Fredrickson Jill , Arteaga Carlos L , Baselga José , Manning Henry C , Mahmood Umar , Ulaner Gary A ,

[30770493] Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker Ariella B , Garrett Joan T , Estrada Mónica Valeria , Moore Preston D , Ericsson Paula González , Koch James P , Langley Emma , Singh Sharat , Kim Phillip S , Frampton Garrett M , Sanford Eric , Owens Philip , Becker Jennifer , Groseclose M Reid , Castellino Stephen , Joensuu Heikki , Huober Jens , Brase Jan C , Majjaj Samira , Brohée Sylvain , Venet David , Brown David , Baselga José , Piccart Martine , Sotiriou Christos , Arteaga Carlos L ,

[30755741] Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman David M , Piha-Paul Sarina A , Won Helen , Rodon Jordi , Saura Cristina , Shapiro Geoffrey I , Juric Dejan , Quinn David I , Moreno Victor , Doger Bernard , Mayer Ingrid A , Boni Valentina , Calvo Emiliano , Loi Sherene , Lockhart Albert C , Erinjeri Joseph P , Scaltriti Maurizio , Ulaner Gary A , Patel Juber , Tang Jiabin , Beer Hannah , Selcuklu S Duygu , Hanrahan Aphrothiti J , Bouvier Nancy , Melcer Myra , Murali Rajmohan , Schram Alison M , Smyth Lillian M , Jhaveri Komal , Li Bob T , Drilon Alexander , Harding James J , Iyer Gopa , Taylor Barry S , Berger Michael F , Cutler Richard E , Xu Feng , Butturini Anna , Eli Lisa D , Mann Grace , Farrell Cynthia , Lalani Alshad S , Bryce Richard P , Arteaga Carlos L , Meric-Bernstam Funda , Baselga José , Solit David B ,

[30745300] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Gene Alterations.

Voss Martin H , Hierro Cinta , Heist Rebecca S , Cleary James M , Meric-Bernstam Funda , Tabernero Josep , Janku Filip , Gandhi Leena , Iafrate A John , Borger Darrell R , Ishii Nobuya , Hu Youyou , Kirpicheva Yulia , Nicolas-Metral Valerie , Pokorska-Bocci Anna , Vaslin Chessex Anne , Zanna Claudio , Flaherty Keith T , Baselga Jose ,

[30711959] Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Sonnenblick Amir , Bailey Andrew , Uziely Beatrice , Untch Michael , Smith Ian , Gianni Luca , Baselga Jose , Jackisch Christian , Cameron David , Bell Richard , Zardavas Dimitrios , Al-Sakaff Nedal , Gelber Richard D , Dowsett Mitch , Leyland-Jones Brian , Piccart-Gebhart Martine J , DE Azambuja Evandro ,

[30694565] MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Novoplansky Ofra , Fury Matthew , Prasad Manu , Yegodayev Ksenia , Zorea Jonathan , Cohen Limor , Pelossof Raphael , Cohen Liz , Katabi Nora , Cecchi Fabiola , Joshua Ben-Zion , Popovtzer Aron , Baselga Jose , Scaltriti Maurizio , Elkabets Moshe ,

[30679318] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Prat Aleix , Brase Jan Christoph , Cheng Yuan , Nuciforo Paolo , Paré Laia , Pascual Tomás , Martínez Débora , Galván Patricia , Vidal Maria , Adamo Barbara , Hortobagyi Gabriel N , Baselga José , Ciruelos Eva ,

[30643254] Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein Robert M , Lee Chung-Han , Shoushtari Alexander N , Hellmann Matthew D , Shen Ronglai , Janjigian Yelena Y , Barron David A , Zehir Ahmet , Jordan Emmet J , Omuro Antonio , Kaley Thomas J , Kendall Sviatoslav M , Motzer Robert J , Hakimi A Ari , Voss Martin H , Russo Paul , Rosenberg Jonathan , Iyer Gopa , Bochner Bernard H , Bajorin Dean F , Al-Ahmadie Hikmat A , Chaft Jamie E , Rudin Charles M , Riely Gregory J , Baxi Shrujal , Ho Alan L , Wong Richard J , Pfister David G , Wolchok Jedd D , Barker Christopher A , Gutin Philip H , Brennan Cameron W , Tabar Viviane , Mellinghoff Ingo K , DeAngelis Lisa M , Ariyan Charlotte E , Lee Nancy , Tap William D , Gounder Mrinal M , D'Angelo Sandra P , Saltz Leonard , Stadler Zsofia K , Scher Howard I , Baselga Jose , Razavi Pedram , Klebanoff Christopher A , Yaeger Rona , Segal Neil H , Ku Geoffrey Y , DeMatteo Ronald P , Ladanyi Marc , Rizvi Naiyer A , Berger Michael F , Riaz Nadeem , Solit David B , Chan Timothy A , Morris Luc G T ,

[30624662] Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J , Calvo V , Ramírez-Merino N , O'Shaughnessy J , Brufsky A , Robert N , Vidal M , Muñoz E , Perez J , Dawood S , Saura C , Di Cosimo S , González-Martín A , Bellet M , Silva O E , Miles D , Llombart A , Baselga J ,

[30624616] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J , Manikhas A , Cortés J , Llombart A , Roman L , Semiglazov V F , Byakhov M , Lokanatha D , Forenza S , Goldfarb R H , Matera J , Azarnia N , Hudis C A , Rozencweig M ,

[30624609] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S , Majewski I , Guarneri V , Nekljudova V , Holmes E , Bria E , Denkert C , Schem C , Sotiriou C , Loi S , Untch M , Conte P , Bernards R , Piccart M , von Minckwitz G , Baselga J ,

[30624607] Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Lenihan D , Suter T , Brammer M , Neate C , Ross G , Baselga J ,

[30624604] Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria J-C , Cortes J , Massard C , Armand J-P , Andreis D De , Ropert S , Lopez E , Catteau A , James J , Marier J-F , Beliveau M , Martell R E , Baselga J ,

[30624599] Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C , Cortés J , De Mattos-Arruda L , Bellet M , Gómez P , Saura C , Pérez J , Vidal M , Muñoz-Couselo E , Carreras M J , Sánchez-Ollé G , Tabernero J , Baselga J , Di Cosimo S ,

[30624595] Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Swain S M , Schneeweiss A , Gianni L , Gao J J , Stein A , Waldron-Lynch M , Heeson S , Beattie M S , Yoo B , Cortes J , Baselga J ,

[30624581] Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Wu Y , Amonkar M M , Sherrill B H , O'Shaughnessy J , Ellis C , Baselga J , Blackwell K L , Burstein H J ,

[30624555] Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W , Jiang T , Nuciforo P , Hatzis C , Holmes E , Harbeck N , Sotiriou C , Peña L , Loi S , Rosa D D , Chia S , Wardley A , Ueno T , Rossari J , Eidtmann H , Armour A , Piccart-Gebhart M , Rimm D L , Baselga J , Pusztai L ,

[30576871] Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.

Gupta Sounak , Vanderbilt Chad M , Cotzia Paolo , Arias-Stella Javier A , Chang Jason C , Zehir Ahmet , Benayed Ryma , Nafa Khedouja , Razavi Pedram , Hyman David M , Baselga José , Berger Michael F , Ladanyi Marc , Arcila Maria E , Ross Dara S ,

[30543347] Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Juric Dejan , Janku Filip , Rodón Jordi , Burris Howard A , Mayer Ingrid A , Schuler Martin , Seggewiss-Bernhardt Ruth , Gil-Martin Marta , Middleton Mark R , Baselga José , Bootle Douglas , Demanse David , Blumenstein Lars , Schumacher Karl , Huang Alan , Quadt Cornelia , Rugo Hope S ,

[30537512] Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Li Zhiqiang , Razavi Pedram , Li Qing , Toy Weiyi , Liu Bo , Ping Christina , Hsieh Wilson , Sanchez-Vega Francisco , Brown David N , Da Cruz Paula Arnaud F , Morris Luc , Selenica Pier , Eichenberger Emily , Shen Ronglai , Schultz Nikolaus , Rosen Neal , Scaltriti Maurizio , Brogi Edi , Baselga Jose , Reis-Filho Jorge S , Chandarlapaty Sarat ,

[30429379] Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello Patrizia , Brea Elliott J , De Stanchina Elisa , Toska Eneda , Chang Aaron Y , Fennell Myles , Seshan Venkatraman , Garippa Ralph , Scheinberg David A , Baselga José , Wendel Hans-Guido , Younes Anas ,

[30422229] Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology-Head & Neck Surgery.

Baselga José ,

[30422165] Failure to Disclose Conflict of Interest in Article Published in JAMA on Detection of Cancer-Related Genes.

Baselga José ,

[30422162] Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology.

Baselga José ,

[30387498] A novel vascular tumour characterized by coexisting HRAS and GNAQ activating mutations.

Castel P , Bagué S , Granell E , Guerrero Vara R , Baselga J , Baselga E ,

[30377213] A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo Marta , Cruz Cristina , Llop-Guevara Alba , Gutiérrez-Enríquez Sara , Ducy Mandy , Ibrahim Yasir Hussein , Gris-Oliver Albert , Pellegrino Benedetta , Bruna Alejandra , Guzmán Marta , Rodríguez Olga , Grueso Judit , Bonache Sandra , Moles-Fernández Alejandro , Villacampa Guillermo , Viaplana Cristina , Gómez Patricia , Vidal Maria , Peg Vicente , Serres-Créixams Xavier , Dellaire Graham , Simard Jacques , Nuciforo Paolo , Rubio Isabel T , Dientsmann Rodrigo , Barrett J Carl , Caldas Carlos , Baselga José , Saura Cristina , Cortés Javier , Déas Olivier , Jonkers Jos , Masson Jean-Yves , Cairo Stefano , Judde Jean-Gabriel , O'Connor Mark J , Díez Orland , Balmaña Judith , Serra Violeta ,

[30376427] Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham Alicia , Srinivasan Preethi , Kemel Yelena , Shia Jinru , Bandlamudi Chaitanya , Mandelker Diana , Middha Sumit , Hechtman Jaclyn , Zehir Ahmet , Dubard-Gault Marianne , Tran Christina , Stewart Carolyn , Sheehan Margaret , Penson Alexander , DeLair Deborah , Yaeger Rona , Vijai Joseph , Mukherjee Semanti , Galle Jesse , Dickson Mark A , Janjigian Yelena , O'Reilly Eileen M , Segal Neil , Saltz Leonard B , Reidy-Lagunes Diane , Varghese Anna M , Bajorin Dean , Carlo Maria I , Cadoo Karen , Walsh Michael F , Weiser Martin , Aguilar Julio Garcia , Klimstra David S , Diaz Luis A , Baselga Jose , Zhang Liying , Ladanyi Marc , Hyman David M , Solit David B , Robson Mark E , Taylor Barry S , Offit Kenneth , Berger Michael F , Stadler Zsofia K ,

[30351999] BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley Thomas , Touat Mehdi , Subbiah Vivek , Hollebecque Antoine , Rodon Jordi , Lockhart A Craig , Keedy Vicki , Bielle Franck , Hofheinz Ralf-Dieter , Joly Florence , Blay Jean-Yves , Chau Ian , Puzanov Igor , Raje Noopur S , Wolf Jurgen , DeAngelis Lisa M , Makrutzki Martina , Riehl Todd , Pitcher Bethany , Baselga Jose , Hyman David M ,

[30335191] Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Lambertini Matteo , Martel Samuel , Campbell Christine , Guillaume Sébastien , Hilbers Florentine S , Schuehly Uwe , Korde Larissa , Azim Hatem A , Di Cosimo Serena , Tenglin Richard C , Huober Jens , Baselga José , Moreno-Aspitia Alvaro , Piccart-Gebhart Martine , Gelber Richard D , de Azambuja Evandro , Ignatiadis Michail ,

[30301790] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco Emiliano , Javier Carmona F , Razavi Pedram , Won Helen H , Cai Yanyan , Rossi Valentina , Chan Carmen , Cownie James , Soong Joanne , Toska Eneda , Shifman Sophie G , Sarotto Ivana , Savas Peter , Wick Michael J , Papadopoulos Kyriakos P , Moriarty Alyssa , Cutler Richard E , Avogadri-Connors Francesca , Lalani Alshad S , Bryce Richard P , Chandarlapaty Sarat , Hyman David M , Solit David B , Boni Valentina , Loi Sherene , Baselga José , Berger Michael F , Montemurro Filippo , Scaltriti Maurizio ,

[30282693] p95HER2-T cell bispecific antibody for breast cancer treatment.

Rius Ruiz Irene , Vicario Rocio , Morancho Beatriz , Morales Cristina Bernadó , Arenas Enrique J , Herter Sylvia , Freimoser-Grundschober Anne , Somandin Jitka , Sam Johannes , Ast Oliver , Barriocanal Águeda Martinez , Luque Antonio , Escorihuela Marta , Varela Ismael , Cuartas Isabel , Nuciforo Paolo , Fasani Roberta , Peg Vicente , Rubio Isabel , Cortés Javier , Serra Violeta , Escriva-de-Romani Santiago , Sperinde Jeff , Chenna Ahmed , Huang Weidong , Winslow John , Albanell Joan , Seoane Joan , Scaltriti Maurizio , Baselga Jose , Tabernero Josep , Umana Pablo , Bacac Marina , Saura Cristina , Klein Christian , Arribas Joaquín ,

[30241001] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Campone Mario , Im Seock-Ah , Iwata Hiroji , Clemons Mark , Ito Yoshinori , Awada Ahmad , Chia Stephen , Jagiełło-Gruszfeld Agnieszka , Pistilli Barbara , Tseng Ling-Ming , Hurvitz Sara , Masuda Norikazu , Cortés Javier , De Laurentiis Michele , Arteaga Carlos L , Jiang Zefei , Jonat Walter , Le Mouhaër Sylvie , Sankaran Banu , Bourdeau Laurence , El-Hashimy Mona , Sellami Dalila , Baselga José ,

[30240327] Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz Cristina , Llop-Guevara Alba , Garber Judy E , Arun Banu K , Pérez Fidalgo José A , Lluch Ana , Telli Melinda L , Fernández Cristian , Kahatt Carmen , Galmarini Carlos M , Soto-Matos Arturo , Alfaro Vicente , Pérez de la Haza Aitor , Domchek Susan M , Antolin Silvia , Vahdat Linda , Tung Nadine M , Lopez Rafael , Arribas Joaquín , Vivancos Ana , Baselga José , Serra Violeta , Balmaña Judith , Isakoff Steven J ,

[30235087] Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia Aditya , Parton Marina , Kümmel Sherko , Estévez Laura G , Huang Chiun-Sheng , Cortés Javier , Ruiz-Borrego Manuel , Telli Melinda L , Martin-Martorell Paloma , López Rafael , Beck J Thaddeus , Ismail-Khan Roohi , Chen Shin-Cheh , Hurvitz Sara A , Mayer Ingrid A , Carreon Daniel , Cameron Scott , Liao Serena , Baselga José , Kim Sung-Bae ,

[30205045] The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi Pedram , Chang Matthew T , Xu Guotai , Bandlamudi Chaitanya , Ross Dara S , Vasan Neil , Cai Yanyan , Bielski Craig M , Donoghue Mark T A , Jonsson Philip , Penson Alexander , Shen Ronglai , Pareja Fresia , Kundra Ritika , Middha Sumit , Cheng Michael L , Zehir Ahmet , Kandoth Cyriac , Patel Ruchi , Huberman Kety , Smyth Lillian M , Jhaveri Komal , Modi Shanu , Traina Tiffany A , Dang Chau , Zhang Wen , Weigelt Britta , Li Bob T , Ladanyi Marc , Hyman David M , Schultz Nikolaus , Robson Mark E , Hudis Clifford , Brogi Edi , Viale Agnes , Norton Larry , Dickler Maura N , Berger Michael F , Iacobuzio-Donahue Christine A , Chandarlapaty Sarat , Scaltriti Maurizio , Reis-Filho Jorge S , Solit David B , Taylor Barry S , Baselga José ,

[30158597] Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.

Ross Dara S , Zehir Ahmet , Brogi Edi , Konno Fumiko , Krystel-Whittemore Melissa , Edelweiss Marcia , Berger Michael F , Toy Weiyi , Chandarlapaty Sarat , Razavi Pedram , Baselga José , Wen Hannah Y ,

[30013179] Genome doubling shapes the evolution and prognosis of advanced cancers.

Bielski Craig M , Zehir Ahmet , Penson Alexander V , Donoghue Mark T A , Chatila Walid , Armenia Joshua , Chang Matthew T , Schram Alison M , Jonsson Philip , Bandlamudi Chaitanya , Razavi Pedram , Iyer Gopa , Robson Mark E , Stadler Zsofia K , Schultz Nikolaus , Baselga Jose , Solit David B , Hyman David M , Berger Michael F , Taylor Barry S ,

[30010759] The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe.

Soria J-C , Baselga J , Piccart M ,

[29989854] Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li Bob T , Shen Ronglai , Buonocore Darren , Olah Zachary T , Ni Ai , Ginsberg Michelle S , Ulaner Gary A , Offin Michael , Feldman Daniel , Hembrough Todd , Cecchi Fabiola , Schwartz Sarit , Pavlakis Nick , Clarke Stephen , Won Helen H , Brzostowski Edyta B , Riely Gregory J , Solit David B , Hyman David M , Drilon Alexander , Rudin Charles M , Berger Michael F , Baselga Jose , Scaltriti Maurizio , Arcila Maria E , Kris Mark G ,

[29902299] Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Powles Ryan L , Redmond David , Sotiriou Christos , Loi Sherene , Fumagalli Debora , Nuciforo Paolo , Harbeck Nadia , de Azambuja Evandro , Sarp Severine , Di Cosimo Serena , Huober Jens , Baselga Jose , Piccart-Gebhart Martine , Elemento Olivier , Pusztai Lajos , Hatzis Christos ,

[29882016] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Rodon Jordi , Pérez-Fidalgo Alejandro , Krop Ian E , Burris Howard , Guerrero-Zotano Angel , Britten Carolyn D , Becerra Carlos , Schellens Jan , Richards Donald A , Schuler Martin , Abu-Khalaf Maysa , Johnson Faye M , Ranson Malcolm , Edenfield Jeff , Silva Antonio P , Hackl Wolfgang , Quadt Cornelia , Demanse David , Duval Vincent , Baselga Jose ,

[29878225] Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Lambertini Matteo , Campbell Christine , Bines José , Korde Larissa A , Izquierdo Miguel , Fumagalli Debora , Del Mastro Lucia , Ignatiadis Michail , Pritchard Kathleen , Wolff Antonio C , Jackisch Christian , Lang Istvan , Untch Michael , Smith Ian , Boyle Frances , Xu Binghe , Barrios Carlos H , Baselga José , Moreno-Aspitia Alvaro , Piccart Martine , Gelber Richard D , de Azambuja Evandro ,

[29872864] Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.

Ptashkin Ryan N , Mandelker Diana L , Coombs Catherine C , Bolton Kelly , Yelskaya Zarina , Hyman David M , Solit David B , Baselga José , Arcila Maria E , Ladanyi Marc , Zhang Liying , Levine Ross L , Berger Michael F , Zehir Ahmet ,

[29793946] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler Maura N , Saura Cristina , Richards Donald A , Krop Ian E , Cervantes Andrés , Bedard Philippe L , Patel Manish R , Pusztai Lajos , Oliveira Mafalda , Cardenas Alison K , Cui Na , Wilson Timothy R , Stout Thomas J , Wei Michael C , Hsu Jerry Y , Baselga José ,

https://antibody-antibodies.com/ | https://gentaur.com/ | https://gen-script.com/ | https://diagenox.com/ | https://clonagen.com/ | http://gentaursearch.com/ | http://gentaurpub.com/ | https://gentaur-online.com/ | http://anti-anti-pdf.com/ | http://gentaur-worldwide.com/

 

Gentaur Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
[email protected] | Gentaur | Gentaur





Gentaur Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected] | Gentaur | Gentaur

 

 




Gentaur France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
[email protected] | Gentaur | Gentaur

Gentaur GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
[email protected] | Gentaur | Gentaur

Gentaur U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
[email protected]

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




Gentaur Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
[email protected] | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






Gentaur Spain
tel:0911876558
[email protected] | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: [email protected] | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

Gentaur Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

[email protected] | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

Gentaur Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
[email protected] | Gentaur | Gentaur